Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - capecitabine, quantity: 500 mg - tablet, film coated - excipient ingredients: titanium dioxide; iron oxide red; lactose monohydrate; magnesium stearate; hypromellose; microcrystalline cellulose; purified talc; croscarmellose sodium - colon cancer,capecitabine sandoz is indicated for the adjuvant treatment of patients with dukes' stage c and high-risk stage b, colon cancer, either as monotherapy or in combination with oxaliplatin.,colorectal cancer,capecitabine sandoz is indicated for the treatment of patients with advanced or metastatic colorectal cancer.,oesophagogastric cancer,capecitabine sandoz is indicated for the first-line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.,breast cancer,capecitabine sandoz is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated.,capecitabine sandoz in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - capecitabine, quantity: 150 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; hypromellose; croscarmellose sodium; titanium dioxide; purified talc; magnesium stearate; iron oxide red - colon cancer,capecitabine sandoz is indicated for the adjuvant treatment of patients with dukes' stage c and high-risk stage b, colon cancer, either as monotherapy or in combination with oxaliplatin.,colorectal cancer,capecitabine sandoz is indicated for the treatment of patients with advanced or metastatic colorectal cancer.,oesophagogastric cancer,capecitabine sandoz is indicated for the first-line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.,breast cancer,capecitabine sandoz is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated.,capecitabine sandoz in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

Israel - English - Ministry of Health

inovamed ltd - capecitabine - film coated tablets - capecitabine 500 mg - capecitabine - adjuvant colon cancer: capecitabine is indicated for the adjuvant treatment of patients following surgery of stage iii (dukesע stage c) colon cancer.colorectal cancer: capecitabine is indicated for the treatment of patients with advanced or metastatic colorectal cancer.advanced gastric cancer: capecitabine is indicated for first line treatment of advanced gastric cancer in combination with chemotherapy.breast cancer combination therapy: capecitabine in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.breast cancer monotherapy: capecitabine is also indicated for the treatment of advanced or metastatic breast cancer after failure of standard therapy including a taxane unless therapy with a taxane is clinically contraindicated.

Israel - English - Ministry of Health

inovamed ltd - capecitabine - film coated tablets - capecitabine 500 mg - capecitabine - adjuvant colon cancer: capecitabine is indicated for the adjuvant treatment of patients following surgery of stage iii (dukesע stage c) colon cancer.colorectal cancer: capecitabine is indicated for the treatment of patients with advanced or metastatic colorectal cancer.advanced gastric cancer: capecitabine is indicated for first line treatment of advanced gastric cancer in combination with chemotherapy.breast cancer combination therapy: capecitabine in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.breast cancer monotherapy: capecitabine is also indicated for the treatment of advanced or metastatic breast cancer after failure of standard therapy including a taxane unless therapy with a taxane is clinically contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - capecitabine -

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - capecitabine -

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi oncology plc - capecitabine - film coated tablet - 500 milligram - capecitabine

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - capecitabine, quantity: 150 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; hypromellose; magnesium stearate; lactose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red - colon cancer ,capecitabine is indicated for the adjuvant treatment of patients with dukes? stage c and high-risk stage b, colon cancer, either as monotherapy or in combination with oxaliplatin.,colorectal cancer,capecitabine is indicated for the treatment of patients with advanced or metastatic colorectal cancer.,oesophagogastric cancer,capecitabine is indicated for the first-line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.,breast cancer,capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated ,capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - capecitabine, quantity: 500 mg - tablet, film coated - excipient ingredients: lactose; magnesium stearate; microcrystalline cellulose; hypromellose; croscarmellose sodium; titanium dioxide; purified talc; iron oxide yellow; iron oxide red - colon cancer ,capecitabine is indicated for the adjuvant treatment of patients with dukes? stage c and high-risk stage b, colon cancer, either as monotherapy or in combination with oxaliplatin.,colorectal cancer,capecitabine is indicated for the treatment of patients with advanced or metastatic colorectal cancer.,oesophagogastric cancer,capecitabine is indicated for the first-line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.,breast cancer,capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated ,capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

Malta - English - Medicines Authority

cipla europe n.v. uitbreidingstraat 80, 2600 antwerp, belgium - capecitabine - film-coated tablet - capecitabine 150 mg - antineoplastic agents